CPX-351 in Higher Risk Myelodysplastic Syndromes | Aplastic Anemia & MDS International Foundation
CPX-351 in Higher Risk Myelodysplastic Syndromes

Clinical Trial: NCT04273802

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:

A phase I/II study of the efficacy of CPX-351 treatment in patients with higher risk myelodysplastic syndromes : as first line treatment or after hypomethylating agents failure.

CPX-351 is an advanced liposomal formulation of daunorubicin and cytarabine encapsulated at a 1:5 ratio.

Patients will receive induction treatment with CPX-351. Patients in response (complete response (CR), complete response with incomplete hematologic improvement (CRi), partial response (PR)) after induction will receive monthly courses of consolidation therapy with CPX-351.

Not yet recruiting
Study Date: 
Fri, 05/01/2020 to Sun, 05/01/2022
Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Drug: CPX-351 in cohort A Drug: CPX-351 in cohort B